# US 2024/0197897 A1 · Heterotandem bicyclic peptide complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197897 A1
- Document ID: US20240197897A1
- Status: Published application
- Kind: A1
- Application number: 18/271,360
- Filed: 2022-01-10
- Published: 2024-06-20
- Earliest claimed: 2021-01-08
- Assignees: Bicycle Tx Limited
- Applicants: Bicycle Tx Limited
- Inventors: Nicholas KEEN; Gemma MUDD; Phil BRANDISH; Katie GAYNOR; Liuhong CHEN; Fay DUFORT; Chris LEITHEISER; Kevin MCDONNELL; Liz REPASH; Sandra UHLENBROICH
- Web page: https://patentgrep.com/patent/US20240197897A1

## CPC

- A61K 47/66: the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- C07K 14/001: {by chemical synthesis}
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to one or more second peptide ligands, which bind to one or more components present on a natural killer (NK) cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.

## Claims

### Claim 1

A heterotandem bicyclic peptide complex comprising:
(a) a first peptide ligand which binds to a component present on a cancer cell;
conjugated via a linker to
(b) one or more second peptide ligands which bind to one or more components present on a natural killer (NK) cell;
wherein each of said peptide ligands comprise a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold.

### Claim 2 (depends on 1)

The heterotandem bicyclic peptide complex as defined in claim 1, wherein said reactives group are cysteine residues.

### Claim 3 (depends on 1)

The heterotandem bicyclic peptide complex as defined in claim 1, wherein the one or more components present on a natural killer (NK) cell is a natural cytotoxicity receptor present on the NK cell surface, such as NKp30, NKp44 and NKp46, in particular NKp46, such as wherein the one or more second peptide ligands comprise one or more NKp46 binding bicyclic peptide ligands.

### Claim 4 (depends on 3)

The heterotandem bicyclic peptide complex as defined in claim 3, wherein the one or more NKp46 binding bicyclic peptide ligands comprise an amino acid sequence which is selected from:
(SEQ ID NO: 5)
CiY[Cba]PDYLCii[dA]DEYCiii;
(SEQ ID NO: 6)
CiYLPDYLCiiGDEYCiii;
(SEQ ID NO: 7)
CiDLTTHNCiiQWGICiii;
(SEQ ID NO: 8)
CiNLQAPCiiMQTGKVCiii;
(SEQ ID NO: 9)
CiNLQNPCiiMKFPCiii;
(SEQ ID NO: 10)
CiYLPDYLCii[dK(PYA)]DEYCiii;
and
(SEQ ID NO: 11)
CiLLHDHCiiPNTHPKLCiii;
wherein Ci, Cii and Ciii represent first, second and third cysteine residues, respectively, and wherein Cba represents β-cyclobutylalanine, dA represents D-Alanine, and PYA represents pentynoic acid, or a pharmaceutically acceptable salt thereof, in particular:
wherein the molecular scaffold is TATA and the one or more NKp46 binding bicyclic peptide ligands optionally comprise N-terminal and/or C-terminal modifications and comprises:
Ac-(SEQ ID NO: 5)-[K(PYA)] (herein referred to as BCY17224);
A-(SEQ ID NO: 6)-A-[dK(PYA)] (herein referred to as BCY15452);
A-(SEQ ID NO: 7)-A-[K(PYA)] (herein referred to as BCY15686);
A-(SEQ ID NO: 8)-A-[K(PYA)] (herein referred to as BCY15687);
A-(SEQ ID NO: 9)-A-[K(PYA)] (herein referred to as BCY18004);
A-(SEQ ID NO: 10)-A (herein referred to as BCY17662); and
A-(SEQ ID NO: 11)-A-[K(PYA)] (herein referred to as BCY18005);
wherein PYA represents pentynoic acid or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The heterotandem bicyclic peptide complex as defined in claim 1, wherein the one or more components present on a natural killer (NK) cell is an Fc receptor present on the NK cell surface, such as a low-affinity Fc gamma receptor (FcγR) selected from FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, and FcγRIIIB, in particular FcγRIIIA (also known as CD16a), such as wherein the one or more second peptide ligands comprise one or more CD16a binding bicyclic peptide ligands.

### Claim 6 (depends on 5)

The heterotandem bicyclic peptide complex as defined in claim 5, wherein the one or more CD16a binding bicyclic peptide ligands comprises an amino acid sequence which is selected from:
(SEQ ID NO: 12)
CiVGLEELGPCiiSDLCiii;
(SEQ ID NO: 13)
CiRWHFSEPCiiGAWCiii;
and
(SEQ ID NO: 14)
CiRWSVEDPCiiGAWCiii;
wherein Ci, Cii and Ciii represent first, second and third cysteine residues, respectively, or a pharmaceutically acceptable salt thereof, in particular:
wherein the molecular scaffold is TBMT and the one or more CD16a binding bicyclic peptide ligands optionally comprise N-terminal and/or C-terminal modifications and comprises:
A-(SEQ ID NO: 12)-A-[K(PYA)] (herein referred to as BCY13886);
A-(SEQ ID NO: 13)-A-[K(PYA)] (herein referred to as BCY20361); and
A-(SEQ ID NO: 14)-A-[K(PYA)] (herein referred to as BCY13883);
wherein PYA represents pentynoic acid or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The heterotandem bicyclic peptide complex as defined in claim 1, wherein the cancer cell is selected from an HT1080, A549, SC-OV-3, PC3, HT1376, NCI-H292, LnCap, MC38, MC38 #13, 4T1-D02, H322, HT29, T47D and RKO tumor cell.

### Claim 8 (depends on 1)

The heterotandem bicyclic peptide complex as defined in claim 1, wherein the component present on a cancer cell is EphA2, such as wherein the first peptide comprises an EphA2 binding bicyclic peptide ligand.

### Claim 9 (depends on 8)

The heterotandem bicyclic peptide complex as defined in claim 8, wherein the EphA2 binding bicyclic peptide ligand comprises an amino acid sequence which is:
(SEQ ID NO: 2)
Ci[HyP]LVNPLCiiLHP[dD]W[HArg]Ciii;
wherein Ci, Cii and Ciii represent first (i), second (ii) and third (iii) reactive groups HyP represents trans-4-hydroxy-L-proline, HArg represents homoarginine, or a pharmaceutically acceptable salt thereof, in particular:
wherein the molecular scaffold is TATA and the EphA2 binding bicyclic peptide ligand optionally comprises N-terminal modifications and comprises:
A-[HArg]-D-(SEQ ID NO: 2) (herein referred to as BCY9594);
wherein HArg represents homoarginine, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The heterotandem bicyclic peptide complex as defined in claim 1, wherein the component present on a cancer cell is PD-L1, such as wherein the first peptide comprises an PD-L1 binding bicyclic peptide ligand.

### Claim 11 (depends on 10)

The heterotandem bicyclic peptide complex as defined in claim 10, wherein the PD-L1 binding bicyclic peptide ligand comprises an amino acid sequence which is:
(SEQ ID NO: 3)
CiSAGWLTMCiiQKLHLCiii;
wherein Ci, Cii and Ciii represent first (i), second (ii) and third (iii) cysteine groups, respectively, or a pharmaceutically acceptable salt thereof, in particular:
wherein the molecular scaffold is TATA and the PD-L1 binding bicyclic peptide ligand optionally comprises N-terminal and/or C-terminal modifications and comprises:
Ac-D-[Harg]-(SEQ ID NO: 3)-PSH (herein referred to as BCY11865);
wherein Harg represents homoarginine, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The heterotandem bicyclic peptide complex as defined in claim 1, wherein the component present on a cancer cell is MT1, such as wherein the first peptide comprises an MT1 binding bicyclic peptide ligand.

### Claim 13 (depends on 12)

The heterotandem bicyclic peptide complex as defined in claim 12, wherein the MT1 binding bicyclic peptide ligand comprises an amino acid sequence which is:
(SEQ ID NO: 4)
CiV[Harg]ECiiA[tBuAla]LFP[Harg]TCiii;
wherein Ci, Cii and Ciii represent first (i), second (ii) and third (iii) cysteine groups, respectively, or a pharmaceutically acceptable salt thereof, in particular:
wherein the molecular scaffold is TATA and the MT1 binding bicyclic peptide ligand optionally comprises N-terminal and/or C-terminal modifications and comprises:
LPP-(SEQ ID NO: 4) (herein referred to as BCY14320);
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The heterotandem bicyclic peptide complex as defined in claim 1, which is any of the complexes listed in Tables A1, A2, A3, B1, C, D and E.

### Claim 15 (depends on 1)

The heterotandem bicyclic peptide complex as defined in claim 1, wherein the pharmaceutically acceptable salt is selected from the free acid or the sodium, potassium, calcium, ammonium salt.

### Claim 16 (depends on 1)

A pharmaceutical composition which comprises the heterotandem bicyclic peptide complex of claim 1, in combination with one or more pharmaceutically acceptable excipients.

### Claim 17 (depends on 1)

A method for preventing, suppressing or treating cancer, in a subject in need thereof, comprising administering to the subject the heterotandem bicyclic peptide complex of claim 1, or a pharmaceutical composition thereof.
